Strides Arcolab Limited announced that its biotech subsidiary Stelis Biopharma previously known as Agila Biotech has entered into Research Collaboration Agreement with Bio-Scaffold International Pte Ltd (BSI), a Singapore based, start-up Company, to research and develop BMP and stem cell loaded 3D printed devices for various applications in orthopaedics, cosmetology/ plastic and reconstructive surgery and dentistry.

The Research will be jointly directed by Dr Anand Iyer, CEO, Stelis Biopharma and Dr Margam Chandrasekaran, CEO/ chief scientist, Bio-scaffold International Pte. Ltd. and each Company will bear the cost of its contribution to the joint research collaboration.

BSI is a pioneer in the application of 3D printing technology for the development of novel, biocompatible scaffolds. Stelis is a cutting edge biotechnology company whose research and development efforts include the development of drug and stem cell loaded devices for the treatment of various medical conditions. Scientists from Stelis and BSI have developed a framework for initial research collaboration which would include working on multiple areas such as BMP-2/7 heterodimer loaded scaffold for orthopaedic applications and BMP2/ BMP7 loaded scaffolds for spinal fusion.

Dr Iyer and Dr Chandrasekaran said that the joint collaboration would help harness the synergies of the two companies in advancing the development of novel 3D printed devices for effectively treating various conditions in the orthopaedic, orthodontic oral/ maxillofacial and plastic/ reconstructive arena.

Stelis Biopharma is building a state-of-the-art R&D in Bangalore (India) to research, and develop biotherapeutic drugs and devices including, but not limited to, biosimilars, biobetters, NBEs, novel formulations and drug loaded devices. The Company is also building a state-of-the art, fully integrated manufacturing facility at Bio-Xcell’s biotechnology park in Nusajaya, within the Iskandar region of Johor, Malaysia for the manufacture of biotherapeutics and devices.

The facility will also provide product and process development and validation services, bioprocess solutions, integrated business services, operational support services, end-user services, leveraging a combination of technology platform and service delivery framework.

Stelis will also provide training and support services as well as consultancy in business, marketing and other allied services to other biotechnology companies.